These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 21554238)
21. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). Cecere LM; Slatore CG; Uman JE; Evans LE; Udris EM; Bryson CL; Au DH COPD; 2012 Jun; 9(3):251-8. PubMed ID: 22497533 [TBL] [Abstract][Full Text] [Related]
22. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928 [TBL] [Abstract][Full Text] [Related]
23. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis. Horita N; Miyazawa N; Tomaru K; Inoue M; Kaneko T Respirology; 2015 Nov; 20(8):1153-9. PubMed ID: 26235837 [TBL] [Abstract][Full Text] [Related]
24. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment. Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120 [TBL] [Abstract][Full Text] [Related]
25. The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T; Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629 [TBL] [Abstract][Full Text] [Related]
26. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK. Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512 [TBL] [Abstract][Full Text] [Related]
27. [Inhaled corticosteroid/beta-2 agonist therapy in moderate COPD]. Yıldırım N Tuberk Toraks; 2010; 58(2):192-201. PubMed ID: 20865575 [TBL] [Abstract][Full Text] [Related]
28. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Fuso L; Mores N; Valente S; Malerba M; Montuschi P Curr Med Chem; 2013; 20(12):1477-95. PubMed ID: 23409722 [TBL] [Abstract][Full Text] [Related]
29. Combination therapy of inhaled corticosteroids and long-acting beta2-adrenergics in management of patients with chronic obstructive pulmonary disease. Sin DD; Johnson M; Gan WQ; Man SF Curr Pharm Des; 2004; 10(28):3547-60. PubMed ID: 15579052 [TBL] [Abstract][Full Text] [Related]
30. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease? Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776 [TBL] [Abstract][Full Text] [Related]
31. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894 [TBL] [Abstract][Full Text] [Related]
32. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404 [TBL] [Abstract][Full Text] [Related]
33. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733 [TBL] [Abstract][Full Text] [Related]
34. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739 [TBL] [Abstract][Full Text] [Related]
35. [Role of ICS/LABA on COPD treatment]. Shibata Y Nihon Rinsho; 2016 May; 74(5):827-32. PubMed ID: 27254954 [TBL] [Abstract][Full Text] [Related]
36. [Triple fix-dose combination for treatment of COPD: convenient and effective]. Worth H; Criée CP Dtsch Med Wochenschr; 2016 Nov; 141(23):1668. PubMed ID: 27855451 [No Abstract] [Full Text] [Related]
37. Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta Pirina P; Foschino Barbaro MP; Paleari D; Spanevello A Respir Med; 2018 Oct; 143():74-81. PubMed ID: 30261996 [TBL] [Abstract][Full Text] [Related]
39. Current appraisal of single inhaler triple therapy in COPD. Lipworth B; Kuo CR; Jabbal S Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248 [TBL] [Abstract][Full Text] [Related]
40. COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV Pavord ID Chest; 2018 Apr; 153(4):782-784. PubMed ID: 29410364 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]